Immunology 2 Flashcards

1
Q

Antibiotics

A

ANTIBIOTICS à an antimicrobial agent produced by a microorganism that kills or inhibits other microorganisms

o Bactericidal è kills bacteria

o Bacteriostatic è stops bacteria growing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cell Wall - Beta lactams

A
  • Penicillin and methicillin
  • Inhibits bacterial cell wall peptidoglycan formation
  • Binds transpeptidases (penicillin-binding proteins)
  • Problems w/ penicillin resistance -> beta lactamase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

DNA - Fluoroquinolones

A
  • Broad spectrum, bactericidal
  • Inhibits DNA replication
    DNA gyrase in gram -ve
  • Topoisomerase IV in gram +ve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ribosomes - Variety (CAMT)

A

o Chloramphenicol (50S) à prevents protein elongation by inhibiting peptidyl transferase activity

o Aminoglycosides (30S) à affects RNA proofreading and causes damage to cell membrane

o Macrolides (50S) à prevents amino-acyl transfer and truncation of polypeptides

o Tetracyclines (30S) à inhibit translation – stops binding of aminoacyl-tRNA to mRNA translation complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Antivirals -> Acyclovir

A

o Can work against HSV, varicella zoster (chickenpox)

o Converted to acyclovir triphosphate only in HSV infected cells due to presence of thymidine kinase

o Acyclovir triphosphate à inhibits DNA polymerase à prevents viral DNA synthesis

· Antiviral drugs we use have to be highly specific for purpose

o Viruses evolve very quickly

o Viruses = obligate intracellular parasites

o Outside completely inert –> can’t do anything

o Genome can be made of DNA or RNA

o Inside cell virus replicates its genome

o Has to co-opt cellular machinery existing inside cell

o Have to find things which are unique to viruses to target like with antibiotics (selective toxicity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Generic Viral Replication Diagram

A

o Virus is on outside, attached to cell and gets in

o Virus falls apart so important viral genome is exposed (nucleocapsids)

o Genome is replicated and used to produce mRNA using host cell nuclear synthetic machinery e.g. Enzymes, ribosomes, vesicles etc.

o Too small to carry synthetic machinery

o Replicated genomes and new capsids reassemble to create new viruses which leave the cell and infect other cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prophylaxis

A

preventing disease before cause is acquired e.g. Vaccination or drug before infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Therapy

A

treating disease once host has been infected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How antiviral drugs work

A

Antiviral drugs target viral enzymes, often substrate analogues such as nucleoside analogues (stops building of DNA/RNA)

· Substrate analogue - looks like real substrate to enzyme but has chemical modifications on it

· Increased understanding of structure of viral components and enzymes can lead to rational drug design

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why acyclovir is the best antiviral agent

A

o Nucleoside analogue

o Mimics guanosine but lacks 3’ -OH groups

o Chain terminator

o Next base can’t be attached due to lack of 3’ OH group

o Given as a prodrug - given as an unphosphorylated form –> not incorporated into strand until it becomes tri-phosphorylated.

o Virus produces enzymes called thymidine kinase which attaches first phosphate to acyclovir –> subsequent phosphorylation to ACVTP by cellular enzymes

o These enzymes only in cells that are affected by virus (like herpes virus)

o Particular substrate has better affinity for viral DNA polymerase so more likely to be copied into and terminate strand of viral genome as opposed to host cell genome

o Resistance rare but maps to thymidine kinase

· Look for specific viral proteins which you could devise small molecules against which only affect what virus is doing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drugs used against Influenza - Amantadine/Rimantadine

A

§ Cyclic amines w/bulky cage-like structures

§ Byproducts of petroleum refinement

§ Active against Influenza A only

§ Block replication of influenza

§ M2 protein - tetrameric ion channel involved in uncoating of virus - drug blocks this ion channel so protons can’t get through and unlock viral core

§ Virus locked in endosomes and won’t initiate infection

§ Single amino acid change in M2 can make virus resistant e.g. Serine to asparagine @ position no. 31, amino acid 31 (S31N mutation has little/no cost to fitness of virus)

§ H3N2 subtype causes vast majority of seasonal flu, and all have M2 proteins with S31N mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drugs used against Influenza - Relenza + Tamiflu

A

§ Crystal structure of neuraminidase protein allowed rational drug design

§ Design a substrate analogue which looks like substrate - sialic acid

§ Neuraminidase cleaves sialic acid form virus otherwise sialic acid binds virus back down onto cell as it’s trying to leave at end of replication

§ Cleavage of sialic acid allows release of new virus particles and continued virus replication in next cell or next host

§ RELENZA - guanidine positive charge

· Modifying it so it sticks more avidly than natural substrate sialic acid (plug drug)

· Enzyme can no longer turn over

§ TAMIFLU - also blocks enzyme but w/diff chemistry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drugs used against influenza - Baloxavir

A

§ Inhibits PA endonuclease (polymerase acidic endonuclease)

§ Resistance

§ Single point mutation PA I38T in PAG target

§ Changes isoleucine to threonine makes virus resistant

§ Common in H3N2 virus especially in children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HIV antivirals

A

o Inhibit virus entry

o Fusion inhibitors stop virus envelope fusing with plasma membrane

o Reverse transcriptase inhibitors (make RNA into DNA)

o Integrase another unique enzymes (DNA gets integrated into our own DNA)

o Protease inhibitors (assembly of virus requires protein to be chopped into pieces)

o AZT or zidovudine - nucleoside analogue

o Combination therapy: to avoid rapid selection for resistance to antiviral drugs

§ You have a drug, which targets a single place on HIV genome, 10,000 nucleotides long with a reverse transcriptase error rate 1 in every 10,000.

§ It’s only going to take one round of replication for the virus to generate the mutation which escapes your drug. But that same genome has another target here,

§ for a second drug.

§ The chances that that genome generate the mutation to your first drug and the mutation to your second drug in the given time, very slim.

§ Now, if you target a different gene of the virus with a third drug that requires a third mutation, the chances that one genome gets all three, very slim.

§ Of course, you’ll get one or the other or the other. But so long as you’re taking all the drugs at once, each singly changed one can’t escape

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antibiotic Resistance

A

High use of antibiotics = selection pressure

o High no. of bacteria, few are resistant to antibiotic à antibiotic kills pathogenic bacteria as well as good bacteria within body (probiotics) à antibiotic resistant bacteria proliferate w/o competition à bacteria can transfer antibiotic-resistance gene to other bacteria via plasmids (conjugation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

4 mechanisms of resistance

A

o Altered target site à methicillin-resistance involved alternative penicillin binding protein (PBP2a) w/low affinity for beta-lactams

o Inactivation of antibiotic à B-lactamase destroys beta lactam ring

o Altered metabolism à increased production of PABA = resistance to sulphonamides

o Decreased drug accumulation à antibiotic efflux pump

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Inhibition of cell wall synthesis

A

Penicillins
Cephalosporins
Bacitracin
Vancomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Inhibition of protein synthesis

A

Chloramphenicol
Erythromycin
Tetracyclins
Streptomycin

19
Q

Inhibition of nucleic acid replication and transcription

A

Quinolones

Rifampin

20
Q

Inhibition of synthesis of essential metabolites

A

Sulfanilamide

Trimethoprim

21
Q

Bacteria evading host defence mechanisms

A

o More likely to replicate + propagate their genes

o More likely to cause disease (their pathogenicity)

o Pathogenicity à ability to cause disease

§ Depends on virulence and infectivity

§ Virulence à features that enhance disease causation

§ Infectivity à general features favouring disease causation

22
Q

3 methods of evading host defences - Evade antibody opsonisation

A

§ 1. Hide antigens
o Bacteria coated w/polysaccharide capsule so antigens are hidden and can’t be recognised

§ 2. Disrupt functions
o Express proteins that means antibody binds to pathogen incorrectly i.e. via Fc and not Fab

o Neutrophils and other immune system components can’t access Fc region so no result from antibody binding (only recognise Fc so if this isn’t shown nothing can happen)

§ 3. Prevent detection
o Secrete proteins that cover up Fc receptors

o E.g. for S. aureus this protein is SSL10 which binds to IgG to cover up Fc receptors

o Also used by TB

§ 4. Degrade antibodies
o Secrete enzymes (proteases) which chop up antibodies so they’re ineffective

§ 5. Modify antigenicity
o Antigenicity = capacity of antigen to produce an immune response inside body

o Determined by how it binds to antibodies (B cell response) or receptors (T cell response)

o Antigen variation à genetic mutations (i.e. recombination) to produce antigen that is diff. in structure and can’t be recognised

o Gram -ve bacteria particularly good at this

—Lipopolysaccharide membrane in gram -ve bacteria

—Variation in sugar content for O antigen part accounts for different serotype of the pathogen

23
Q

3 methods of evading host defences - Evade complement opsonisation

A

§ 1. Inhibit convertases
o Secrete proteins which inhibit C3 and C5 convertases - as a result this prevents:

§ C3b deposition

§ C3a formation

§ C5a formation

o Therefore, less chemoattraction

o S. aureus protein SCIN binds to C3bBb and inhibits

formation of C3 convertase and C5 convertase

o C3 and C5 convertases convert substrates into C3 and C5 which in turn can lead to chemoattraction of neutrophils and also inflammation

§ 2. Inhibit complement components
o Secrete proteins which prevent:

§ Binding of factor B to C3 à essential for C3 convertases to recognise C3 and convert it into C3a

§ C3dg binding CR2 à CR2 is a complement receptor expressed on B cells, if C3dg can’t bind to CR2 – no B cells are activated

o S. aureus protein Efb binds C3d in C3 which induces conformational change which prevents binding of factor B to C3 and C3dg binding to CR2

§ 3. Degrade complement components
o Proteases cleave C3 or C5 into 2 non-functional forms

§ 4. Recruit host-derived regulators
o Recruit regulators of complement via surface proteins, inactivates components e.g. C3b

o Genetic mutations – express copies of human complement regulators à can turn off complemen

24
Q

3 methods of evading defences - Evade neutrophil functions

A

§ 1. Inhibit chemotaxis
o Inhibiting chemotactic receptors

o Secrete proteins which inhibit chemotaxis

o S. aureus CHIPs inhibits chemotaxis and activation

§ 2. Inhibit detection of bacteria
o Blocking Fc receptors preventing detection of IgG opsonised bacteria

o Secrete proteins that bind to Fc receptors on neutrophils –

preventing phagocytosis

o Neutrophils need to bind to Fc region of antibody (which is bound to pathogen) to trigger phagocytosis of that pathogen

o S. aureus FLIPr and SSL5 block Fc receptors

§ 3. Kill neutrophils
o Kill neutrophils à by releasing toxins

o Express surface proteins that are stimulatory receptor antagonists

o Express surface proteins that activate inhibitory receptors

o Secrete molecules that neutralise toxins

o Manipulate intracellular signalling à escape endosome or phagosome

o Prevent fusion of phagosome w/lysosomes

o Survive well in phagolysosome – mainly applies to intracellular pathogens

o Change their surface

§ 4. Stimulate inhibitory receptors

§ 5. Disrupt intracellular signalling

25
Q

Complement system

A
  • Circulating & membrane-associated proteins (usually proenzymes) that are important in defense against microbes
  • Cascade involves sequential activation of enzymes, sometimes called an enzymatic cascade
  • The central component of complement is a plasma protein called C3, cleaved by enzymes (C3 convertase)
  • All pathways lead to the production of C3b, a major proteolytic fragment which activate downstream complement proteins and achieve various effects (all pathways have same effector functions)

· Complement system is composed of a large number of proteins that react w/ one another to opsonise pathogens or to directly kills them by MAC formation

· Key steps

o 1. Initiation

o 2. Formation of C3 convertase

o 3. Formation of C5 convertase

o 4. MAC formation à MAC produces pore in bacterial cell membrane to lead to lysis

26
Q

Viral evasion of immune system - Infect “immune privileged sites”

A

o Sites with reduced immune surveillance including the eye, CNS and testes

§ Actions of immune system in these sites would cause unnecessary damage

o Latency of HSV in sensory neurones

o Measles in CNS

27
Q

Viral evasion of immune system - Escape mutations

A

o Changes of amino acids in peptide epitopes (the antigen) interfere w/MHC binding (if at anchor residue – forms pocket to stabilise interaction between TCR and antigen) or T cell recognition is at contact residue (where TCR interacts w/antigen)

o Loss of MHC binding – therefore no antigen presentation

o No T cell recognition à no T cell activation

o OR may change viral peptide so T cell becomes unresponsive rather than activated

28
Q

Viral evasion of immune system - Down regulate MHC

A

o Endocytosis of MHC molecules once they’re expressed

o Retention of MHC in ER

o Potentially can block any step in pathway

29
Q

Viral evasion of immune system - Many virus can escape antibody recognition

A

o Human rhinoviruses that cause the common cold exist as hundreds of antigenically distinct serotypes.

o HIV exists as multiple clades or quasi-species.

o Hepatitis B virus (HBV) and Ebola virus encode secreted surface antigens that mop up antibody, stopping it reaching virus particles or infected cells.

o Dengue Virus exists as 4 serotypes. Previous infection with one serotype followed by infection with a different serotype can lead to antibody dependent enhancement of disease as virus enters immune cells via antibody and the Fc-Receptor. This triggers Dengue Haemorrhagic Fever.

o Influenza viruses mutate and evolve to change year on year, antigenic drift.

o Influenza viruses can also acquire completely new antigens by reassortment with animal viruses; This is called antigen shift and can lead to pandemics.

o This has consequences for vaccination. For example:

§ Too many rhinovirus serotypes make finding a cold vaccine difficult.

§ A new influenza vaccine is required each year to reflect the circulating virus types.

30
Q

Interferons

A

o Virally infected cells produce and release small proteins called interferons, which play a role in immune protection against viruses.

o Interferon (IFN) is induced by molecules made by viruses that are sensed by the cell as foreign or in the wrong cellular location. For example, double-stranded RNA, RNA that lacks a 5’ cap, or DNA in the cytoplasm.

o Interferon is secreted from the infected cell and binds to interferon receptors. IFN initiates the antiviral state in the infected cells and in surrounding cells.

o The Antiviral state involves transcription of hundreds of genes that block viral replication, for example 2’5’ oligoadenylate synthetase and protein kinase R.

o Interferon activates Natural Killer cells and systemic antiviral responses.

31
Q

Type I IFNs

A

Type I IFNs are IFN-α and IFN-β

· - IFN-β is secreted by all cells and the IFNαR receptor is present on all tissues.

· - Plasmacytoid dendritic cells (PDCs) are specialist IFN-α secreting cells. - There is one gene for IFN- β, but 13/14 isotypes of IFN-α.

  • In response to viral infections
  • Interferes with viral replication in neighboring cells
  • Type I interferon actions
    o Cell sensor recognises viral infection, triggers transcription of Type-1 interferon
    o Paracrine effects – IFN diffuses to neighbouring cells, attaching to their Type I IFN receptors
    o Defense of nearby cells. Cells secrete substances that destroy viruses
    o Also activates inflammatory cells (e.g. NK cells)
32
Q

Type II IFNs

A

· Type II IFN is IFN-γ

· - Produced by activated T cells and NK cells.

· - Signals through a different receptor IFN-γR

33
Q

Type III IFNs

A

Type III IFN is IFN-λ

· Signals through receptors IL28R and IL10-β also known as IFN-λ -receptors that are mainly present on epithelial surfaces

· Viruses like Hepatitis B and Influenza virus can block production of Interferon by inhibition of IFN transcription (HBV) or Influenza virus produced a protein (NS1) that counters RNA sensing and prevents polyA processing.

34
Q

Vaccination

A

· Stimulates immune system à create memory

· Artificially acquired active immunity

· Ideal vaccine

o Completely safe

o Easy to administer

o Single dose, needle free

o Cheap

o Stable – doesn’t react inside body

o Active against all variants – as many stereotypes as possible

o Effective – life-long protection

· Herd immunity à break chain of transmission

· Summary of immune response to infection

o Pathogen invades body

o DCs use pattern recognition receptors (PRRs) to recognise damage associated molecular patterns (DAMPs) or pathogen associated molecular patterns (PAMPs) and then become activated

§ DCs activate B and T cells in lymph nodes

§ Activate DCs without tissue damage

o DCs migrate to secondary lymphoid tissues to activate appropriate B cell or T cell (antigen presentation)

o Macrophages can also phagocytose pathogen if activated

o DAMPs include high extracellular ATP

o PAMPs include bacterial cells wall components e.g. flagellin or LPS

35
Q

B cells response to Vaccines

A

· Affinity maturation (B cells only)

o Somatic hypermutation à induction of point mutations into VDJ regions of variable region of antibody

o May result in conformational changes in antigen-binding site à if this results in higher affinity binding between antigen and antibody à this B cell population will receive positive survival signals by T Follicular helper cells in thymus

o Try to make it closer match to antigen

o Ones with lower affinity binding receive death signals

· Secondary response is faster and stronger

o Stronger means higher quantity of antibody is released

· Immune response to vaccine

o 1. Clonal expansion

o 2. Contract – make no. cells smaller

o 3. Keep some as memory cells

o Secondary expansion – memory cells expand

· Vaccines – boost immune response, kill infected cells etc.

36
Q

Vaccines

A

Vaccines are made of:

o Adjuvant (normally alum) à to enhance and modulate immune response

§ Potentiate immune response by interacting w/PAMPs and DAMPs – causes cell to release inflammatory mediators

§ Recognised by PRRs on DCs à present antigen to T cells

§ Stronger immune response by stimulating both innate and adaptive immune system

o Excipient à water, buffers, salts, saccharides and proteins, maintain pH, osmolarity, stability, preservative e.g. phenoxyethanol, thiomersal etc. (single dose vaccines don’t need preservative)

o Antigen in various forms à to stimulate immune response to target disease

§ Inactivated protein e.g. tetanus toxoid

§ Recombinant protein e.g. Hep B

§ Live attenuated pathogen e.g. polio/BCG

§ Dead pathogen e.g. Split Flu vaccine

§ Carbohydrate e.g. S. pneumoniae

37
Q

Live attenuated vaccines

A

· OPV (Polio), BCG, MMR, Chickenpox, LAIV (influenza)

· Weakened – contain mutations to stop disease-causing ability but can still be recognised by immune system as foreign (loses virulent factors)

· Because they’re live they can replicate inside host and recognised as foreign à generate an innate response and boost immune response

· PROs:

o Can replicate (so only need low doses)

o Strong immune response (life-long immunity)

o Can induce string local immune response in site where particular infection is most likely to occur (LAIV)

· CONs:

o May lose key antigens on attenuation

o May develop virulent factors

o Can infect immunocompromised

o Can be outcompeted by other infections

38
Q

Dead vaccines

A

· Influenza split vaccine, Hepatitis A

· Organism is grown and then killed either chemically (e.g. w/phenol or formaldehyde) or by heating

· Antigenic components still intact + so can stimulate B cell and T cell responses

· PROs:

o Stimulates immune response effectively

o Cheap

o Simple

· CONs:

o Antigen can be altered or destroyed in inactivation

o Need to grow live pathogen (quite risky for influenza)

o Live pathogen can contaminate the vaccine (polio)

o Vaccine induced pathogenicity is a risk

39
Q

Recombinant protein vaccines

A

· Hepatitis B surface antigen (HepBsAg)

· Recombinant protein from antigen (cultured in yeast)

· Immune system will generate neutralising antibodies against the antigens

· PROs:

o Pure

o Safe

o Good immune response against targeted part of pathogen

o Low strain variation

· CONs:

o Expensive

o Protein structure may not be exactly the same (post translational modifications may be absent)

40
Q

Inactivated protein vaccines

A

· Tetanus and diphtheria toxoids

· Chemically inactivate bacterial exotoxin

· Stimulates production of complementary antibody that will block action of that exotoxin

· PROs:

o Simple to produce

o Cheap

o Relatively safe

o Highly immunogenic

o High protective efficacy

· CONs:

o Not all pathogens produce toxins

o Need good understanding of toxin produced

o Sometimes toxin isn’t inactivated fully

41
Q

Conjugated vaccines

A

· S. pneumoniae, HIB

· Polysaccharide coat component is coupled to an immunogenic carrier protein

· Protein stimulated T cell response via CD4 which improves B cell immune response (T cells help affinity maturation take place)

· PROs:

o Improves immunogenicity

o Highly effective against infections caused by encapsulated bacteria

· CONs:

o Expensive

o Strain specific

42
Q

Complement pathways

A

The three complement pathways
- Classical pathway
o Triggered when: antibodies bind to microbes or other antigens
o In the classical pathway, the complement is activated by interaction between C1 and Ab Dc. IgM, IgG1, IgG3 efficiently fix complement.
o A single C1q complex (made up of C1q, r, s) interacts simultaneously with 2 Fc regions (at least), which bind antibody molecules. The antibody will only be able to form a bridge between the complex and antigen when it is bound to an antigen itself
- Mannose-Binding Lectin Pathway
o Triggered when: plasma protein (mannose-binding lectin) binds to terminal mannose residues on surface glycoproteins of microbes.
o There is a particular spatial arrangement of mannose/ sugar molecules on surfaces of bacteria/microbes
o Whereas normal cells do not have such a spatial arrangement – will not activate it
o Activate the proteins of classical pathway
o Absence of antibody
- Alternative pathway
o Triggered when: some complement proteins are activated on microbial surfaces and cannot be controlled (in microbes)
o This is because C3 itself is not stable, will undergo spontaneous low-level auto-activation
o Inhibitory mechanism: host cells contain inhibitors

43
Q

Major functions of complement systems

A
  • Formation of analaphylatoxins (C3a, C5a)
    o Anaphylatoxin: the small fragment of the complement proenzyme (formed when proenzyme C3 is cleaved), aka C3a
    o It can recruit and stimulate immune cells by acting as chemo-attractants/chemotaxins, recruiting cells to site of tissue injury or invasion
    o It has direct effects on blood vessels by increasing vascular permeability, and increasing cell stickiness (facilitating diapedesis of cells)
    o Excess complement activity may lead to anaphylatic shock
  • Opsonisation (C3b, C5a, lectin)
    o Opsonins enhance phagocytosis
    o Complement fragments (C3b) coat bacterium surface, facilitating takeup by phagocyte
    o Complement fragments may also simultaneously bind to complement receptors on phagocytes
    o Phagocytosis is also further enhanced by macrophage activation by other complement fragments (C5a)
  • Clearing of immune complexes
    o Immune complexes can become large and insoluble; it is a network of antibody & antigen formed due to absence of complement. It can become trapped in tissue and cause tissue injuries
    o Covalent bonding of C3b to antibody in a complex inhibits lattice formation and maintains solubility of complexes
    o C3b-coated complexes attach to receptors on rbc and are removed from circulation via liver and spleen
  • Complement-mediated cytotoxicity (C5b, 6-9)
    o Formation of a polymeric protein complex (membrane attack complex) that inserts into the microbial cell membrane, disturbing the permeability barrier and causing either osmotic lysis or apoptotic death of microbe
    o Terminal products of complement activation